Drug results: 1
favipiravir | A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host enzymes and selectively inhibits the influenza viral RNA-dependent RNA polymerase. Several studies reported the use of favipiravir for the treatment of COVID-19 but additional data are needed to substantiate the initial reports. Given the lack of pharmacokinetic and safety data for the high favipiravir dosages proposed for treatment of COVID-19, the drug should be used with caution at such dosages. |
Citing DrugCentral © 2024. License